Brief: Transgene Q1 Cash And Cash Equivalents At EUR 46.8 Mln
May 10 (Reuters) - Transgene SA TRNG.PA :
* TRANSGENE: Q1 2022 FINANCIAL POSITION AND BUSINESS UPDATE
* EUR 46.8 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH
31,
2022 - CONFIRMED FINANCIAL VISIBILITY UNTIL END OF 2023
* ALL OF TRANSGENE’S PRECLINICAL AND CLINICAL ASSETS
PROGRESSED IN
LINE WITH EXPECTATIONS IN Q1 2022
Source text for Eikon: ID:nBw5c67WDa
Further company coverage: TRNG.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587696600;))
Recent news on Transgene SA
See all newsFrance's Transgene H1 operating income falls on lower tax credit
Transgene jumps 20% on positive cancer vaccine data in early trial
Brief: Transgene & NEC Bio Sign License Agreement To Prepare Next Steps Of Development Of TG4050 In Head & Neck Cancer
Brief: Transgene SA Says Myvac Platform To Initiate Phase 1 Trial In Second Indication In 2026
France's Transgene 2025 net loss widens on higher financial costs